On June 18, 2025, Adaptive Biotechnologies (ADPT, Financial) received a significant boost as Craig-Hallum initiated coverage on the stock with a “Buy” rating. Analyst John Wilkin led the assessment, underscoring a positive outlook for the company's market prospects.
The current price target for Adaptive Biotechnologies (ADPT, Financial) has been set at USD 15.00. This marks the initial price target announcement for the company by Craig-Hallum, aimed at guiding investors on potential future valuations. This strategic move could influence investor confidence and contribute to future trading activities.
Adaptive Biotechnologies (ADPT, Financial) operates on the NASDAQ exchange and continues to draw attention from analysts and investors alike due to its innovations and potential market performance. As of today, there is no prior rating or price target from Craig-Hallum, making this initiation a key development for stakeholders and market watchers.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Adaptive Biotechnologies Corp (ADPT, Financial) is $11.60 with a high estimate of $13.00 and a low estimate of $9.00. The average target implies an upside of 14.40% from the current price of $10.14. More detailed estimate data can be found on the Adaptive Biotechnologies Corp (ADPT) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Adaptive Biotechnologies Corp's (ADPT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Adaptive Biotechnologies Corp (ADPT, Financial) in one year is $8.51, suggesting a downside of 16.07% from the current price of $10.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Adaptive Biotechnologies Corp (ADPT) Summary page.
